Recombinant Human PD1 Protein，His

The study of PD-1 (programmed cell death protein 1) recombinant protein has gained significant attention in recent years, primarily due to its pivotal role in regulating immune responses and its implications in cancer immunotherapy. PD-1 is an inhibitory receptor expressed on T cells and other immune cells, which, upon binding to its ligands PD-L1 and PD-L2, downregulates immune activation and promotes self-tolerance, thereby preventing autoimmunity. However, many tumors exploit this pathway to evade immune surveillance, leading to the development of PD-1/PD-L1 inhibitors as a therapeutic strategy. The production of recombinant PD-1 proteins facilitates a deeper understanding of its structure, function, and interactions, which are critical for the design of effective inhibitors. Moreover, studying PD-1 in its recombinant form allows researchers to explore potential biomarkers for patient selection and treatment responses. As the field of immunotherapy evolves, recombinant PD-1 proteins are being utilized in various applications, including vaccine development, diagnostic assays, and as a basis for engineered immune cells. Overall, research on PD-1 recombinant proteins is central to advancing therapeutic strategies that enhance anti-tumor immunity and improve outcomes for cancer patients.